Nuvation Bio Inc (NUVB) is a Healthcare · Biotechnology company listed on NYSE. Price $5.85 (-3.62%), Market cap $1.54B, 52-week low–high $1.71 ~ $9.54.
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. It is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 3 clinical trials for the maintenance treatment of high-risk or high-grade IDH1-mutant astrocytoma with safusidenib against placebo. The company was founded in 2018 and is headquartered in New York, New York.
Financial statements, price targets, institutional (13F) holdings and related news for Nuvation Bio Inc are updated in real time on BlackAll Trade.
Nuvation Bio Inc trades at $5.85 (-3.62%). Real-time quotes and charts are available on BlackAll Trade.
Nuvation Bio Inc has a market cap of about $1.54B.
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 in